Clinical outcomes of effectiveness and safety in cataract patients implanted with the novel hybrid extended depth-of-focus intraocular lens AM2UH: a prospective study

新型混合型扩展景深人工晶状体AM2UH在白内障患者中的临床疗效和安全性:一项前瞻性研究

阅读:1

Abstract

BACKGROUND: AM2UH was a novel bifocal hybrid extend the depth of focus (EDF) intraocular lens (IOL). This study is to evaluate the effectiveness and safety by comparing it with a monofocal IOL (AW-UV). METHODS: A prospective, comparative, single-center study. 37 patients (37 eyes) were implanted with novel hybrid EDF IOL model AM2UH. 36 patients (36 eyes) were implanted with monofocal IOL model AW-UV. At 6 months postoperatively, the visual acuity (uncorrected and distance corrected), defocus curves, refractive outcomes, contrast sensitivity, questionnaires of visual quality were assessed and compared between 2 groups. RESULTS: Compared to AW-UV, AM2UH showed non-inferior monocular corrected distance visual acuity (p > 0.05), but superior intermediate and near visual acuity (all p < 0.05). Additionally, AM2UH provided satisfactory DCVA at 1.0 m (0.15 ± 0.07 logMAR) and an extended depth of focus, with an increase of 1.08 D at the 0.2 logMAR. AM2UH group showed high spectacle independence rate and satisfaction rates about intermediate and near vision. There were no significant differences in contrast sensitivity, the incidences of photic phenomena, intraocular pressure and adverse events between 2 groups. CONCLUSION: AM2UH IOL is an effective and safe EDF IOL that offers satisfactory intermediate vision and distance vision, improves near vision, and delivers an extended visual range while maintaining favorable visual quality. CLINICAL TRIAL REGISTRATION: Identifier: MR-50-25-086616.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。